The Pharmacy Times® Chronic Lymphocytic Leukemia Resource Center is a comprehensive resource for clinical news and expert insights on treatments for chronic lymphocytic leukemia.
April 17th 2024
This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Revolutionizing Multiple Myeloma Care: CAR T-Cell Therapy, Bispecific Antibodies, and Patient-Centered Strategies
1.0 Credit / Oncology, Hematologic Cancer
View More
Pharmacists in the Oncology Setting: Financial and Clinical Impact is Significant
November 3rd 2022In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.
Read More
Zanubrutinib Shows Superior Progression-Free Survival vs Ibrutinib in Chronic Lymphocytic Leukemia
October 13th 2022Zanubrutinib (Brukinsa) is a small molecule Bruton’s tyrosine kinase inhibitor under evaluation as a monotherapy and in combination with other treatments for various B-cell malignancies.
Read More
HSSP Leads to High Rate of Acid Suppression Therapy Substitution
This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed acalabrutinib.
Read More
Oncology Overview: Treatment of Chronic Lymphocytic Leukemia with Ibrutinib, Venetoclax
August 16th 2022Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.
Read More
Managing AEs With BTK Inhibitors in CLL
March 28th 2022Lisa Nodzon, PhD, ARNP, AOCNP; Katie Tobon, PharmD, BCOP; and Javier Pinilla-Ibarz, MD, PhD, share insight on strategies for the monitoring and management of BTK inhibitor–associated toxicities in CLL and review the importance of a multidisciplinary approach to treatment.
Watch